Chiara Raggi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8365189/publications.pdf

Version: 2024-02-01

50 papers	4,016 citations	257357 24 h-index	243529 44 g-index
50 all docs	50 docs citations	50 times ranked	5612 citing authors

#	Article	IF	Citations
1	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	8.2	1,155
2	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	8.2	964
3	Hepatocyte growth factor/c-metsignaling is required for stem-cell-mediated liver regeneration in mice. Hepatology, 2012, 55, 1215-1226.	3.6	159
4	Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types. Gastroenterology, 2013, 145, 221-231.	0.6	153
5	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115.	1.8	130
6	Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene, 2016, 35, 671-682.	2.6	122
7	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology, 2018, 68, 949-963.	3.6	106
8	An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer. Science Translational Medicine, 2010, 2, 54ra77.	5.8	92
9	Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity. Carcinogenesis, 2010, 31, 804-811.	1.3	84
10	Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology, 2014, 59, 2251-2262.	3.6	75
11	Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2. Cancer Research, 2014, 74, 4752-4761.	0.4	74
12	Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology, 2011, 54, 1031-1042.	3.6	72
13	Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene, 2011, 30, 4175-4184.	2.6	66
14	Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts. Journal of Hepatology, 2015, 62, 198-207.	1.8	66
15	Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma. Cancer Research, 2010, 70, 8264-8269.	0.4	65
16	Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Scientific Reports, 2017, 7, 17667.	1.6	60
17	Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1373-1385.	1.8	60
18	Cell death and impairment of glucose-stimulated insulin secretion induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the Î²-cell line INS-1E. Toxicology and Applied Pharmacology, 2007, 220, 333-340.	1.3	55

#	Article	IF	Citations
19	The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium. International Journal of Molecular Sciences, 2018, 19, 2885.	1.8	53
20	Metabolic reprogramming in cholangiocarcinoma. Journal of Hepatology, 2022, 77, 849-864.	1.8	49
21	Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer. Oncotarget, 2017, 8, 7094-7115.	0.8	36
22	RNA-seq reveals distinctive RNA profiles of small extracellular vesicles from different human liver cancer cell lines. Oncotarget, 2017, 8, 82920-82939.	0.8	31
23	The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. Oncogenesis, 2019, 8, 61.	2.1	27
24	Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Liver International, 2019, 39, 79-97.	1.9	25
25	Plasma membrane Î³-glutamyltransferase activity facilitates the uptake of vitamin C in melanoma cells. Free Radical Biology and Medicine, 2004, 37, 1906-1915.	1.3	21
26	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. Cancers, 2019, 11, 519.	1.7	21
27	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. American Journal of Pathology, 2019, 189, 2090-2101.	1.9	17
28	Iron Metabolism in Liver Cancer Stem Cells. Frontiers in Oncology, 2019, 9, 149.	1.3	17
29	Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. Frontiers in Pharmacology, 2019, 10, 604.	1.6	16
30	Methylation and liver cancer. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 564-571.	0.7	15
31	The proteaseâ€inhibitor SerpinB3 as a critical modulator of the stemâ€like subset in human cholangiocarcinoma. Liver International, 2022, 42, 233-248.	1.9	15
32	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2246-2256.	1.8	14
33	Role of Chemokines in the Biology of Cholangiocarcinoma. Cancers, 2020, 12, 2215.	1.7	13
34	Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells, 2020, 9, 596.	1.8	13
35	Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. JHEP Reports, 2022, 4, 100444.	2.6	13
36	Extracellular Signalâ€Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. Hepatology, 2021, 74, 2007-2020.	3.6	12

#	Article	IF	Citations
37	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Digestive and Liver Disease, 2014, 46, 363-368.	0.4	11
38	The Role of the Hedgehog Pathway in Cholangiocarcinoma. Cancers, 2021, 13, 4774.	1.7	10
39	A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. Cancers, 2021, 13, 2051.	1.7	8
40	Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. Oncotarget, 2019, 10, 3931-3938.	0.8	6
41	Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. Cancers, 2019, 11, 454.	1.7	4
42	Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. Frontiers in Oncology, 2022, 12, 771418.	1.3	4
43	DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells, 2022, 11, 1463.	1.8	3
44	Nuclear translocation of glutathione transferase omega is a progression marker in Barrett's esophagus. Oncology Reports, 1994, 21, 283.	1.2	2
45	Establishment and characterization of a new spontaneously immortalized ERâˆ’/PRâˆ’/HER2+ human breast cancer cell line, DHSF-BR16. Scientific Reports, 2021, 11, 8340.	1.6	2
46	Abstract 1644: siRNA targeting of cell cycle kinase Wee1 inhibits hepatocullar carconima growthin vitroandin vivo. , 2011, , .		0
47	Abstract 2452: Generation of hepatocellular carcinomas with cancer stem cell properties from primary mouse hepatocytes. , 2011, , .		0
48	Abstract 2460: Tumorigenic potential is independent of sphere phenotype in liver cancer. , 2011, , .		0
49	Abstract 4261: Epigenetic reprogramming affects malignant properties of human liver cancer cells. , 2012, , .		0
50	Abstract 2677: Role of CLEC4D in inflammation-driven liver carcinogenesis. , 2017, , .		0